SLNSilence Therapeutics plc
- GlobeNewswire
The Catalysts are Back: Socket Mobile Breaks Out while Biotechs Race Toward Major Milestones
DENVER, Aug. 10, 2026 (GLOBE NEWSWIRE) -- (247mnn.com) — Today's market is being driven by a potent combination of corporate catalysts, clinical readouts and investor anticipation, with Socket Mobile (NASDAQ:SCKT) ...
- BusinessWire
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% Both divesiran dose groups showed ...
- BusinessWire
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
Silence Therapeutics plc, (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second quarter ended June 30, ...
- BusinessWire
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
Silence Therapeutics plc, (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase ...
- Analyst Upgrades
Cantor Fitzgerald Initiates Coverage On Silence Therapeutics with Overweight Rating
Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Silence Therapeutics with a Overweight rating. ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics with a Buy and maintains $75 price target. ...
- Analyst Upgrades
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
Silence Therapeutics says SANRECO data show sustained polycythemia vera benefits as analysts weigh divesiran's profile against rusfertide. ...
- BusinessWire
Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life Follow-up data show substantial reductions in phlebotomy use persisting after final dose Phase 2 ...
- BusinessWire
Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside ...
- BusinessWire
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, ...
- BusinessWire
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for topline results in August 2026 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global ...
- BusinessWire
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
Topline results for Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for third quarter of 2026 Silence Therapeutics plc, Nasdaq: SLN, a global clinical-stage company ...
- BusinessWire
Silence Therapeutics Announces Leadership Changes
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the ...
- BusinessWire
Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference
Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat at the Jefferies ...
- BusinessWire
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong balance sheet and cash runway into 2028 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or ...
- BusinessWire
Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)
Rapid Completion of Phase 2 Enrollment Reflects Ongoing Momentum for Divesiran as First-in-Class siRNA for PV Topline Results Anticipated in 3Q'26 Silence Therapeutics plc (NASDAQ:SLN), a global clinical-stage ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Silence Therapeutics with a Buy and maintains $75 price target. ...
- Earnings Call Transcripts
Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript ...
- BusinessWire
Silence Therapeutics to Participate in September Investor Conferences
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in the ...
- Analyst Upgrades
Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $35 Price Target
Chardan Capital analyst Keay Nakae maintains Silence Therapeutics with a Buy and maintains $35 price target. ...
- SEC
10-Q Form - Quarterly report [Sections 13 or 15(d)] - Silence Therapeutics plc (0001479615) (Filer)
Quarterly report [Sections 13 or 15(d)] ...
- SEC
8-K Form - Current report, items 2.02 and 9.01 - Silence Therapeutics plc (0001479615) (Filer)
Current report, items 2.02 and 9.01 ...
- BusinessWire
Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
‒ Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in PV ‒ SANRECO Phase 2 Study On-Track for Complete Enrollment by Year-End 2025 Silence ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - Silence Therapeutics plc (0001479615) (Issuer)
Statement of changes in beneficial ownership of securities ...
- SEC
4 Form - Statement of changes in beneficial ownership of securities - Silence Therapeutics plc (0001479615) (Issuer)
Statement of changes in beneficial ownership of securities ...